6-Methoxy-5-(4-methyl-1H-imidazol-1-YL)pyridin-2-amine → N-(6-Methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-4-methyl-2-(4-methylthiazol-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine

HRID 403

反応式

HRID 403 の反応式
COc1nc(N)ccc1-n1cnc(C)c1.Cc1csc(C2CN(C)Cc3ccc(Cl)nc3O2)n1>CC(=O)O.CC(=O)O.COCCOC.O=C([O-])[O-].[Cs+].[Cs+].[Pd].c1ccc(-c2ccccc2P(C2CCCCC2)C2CCCCC2)cc1>COc1nc(Nc2ccc3c(n2)OC(c2nc(C)cs2)CN(C)C3)ccc1-n1cnc(C)c1

参加物

7

反応条件

温度
110 °C

実験手順

To 8-chloro-4-methyl-2-(4-methylthiazol-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepine (120 mg, 0.41 mmol) in DME (3 mL) were 6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-amine (83 mg, 0.41 mmol), cesium carbonate (198 mg, 0.61 mmol), 2-(Dicyclohexylphosphino)biphenyl (14.22 mg, 0.04 mmol) and Palladium acetate (9.11 mg, 0.04 mmol) added. The reaction was heated to 110°C for 180 min under N2 atmosphere. The solids were filtered off and washed with DCM, the solvents were evaporated and the crude product was purified by silica flash chromatography, MeOH, 0-10%, in DCM yielding N-(6-methoxy-5-(4-methyl-1H-imidazol-1-yl)pyridin-2-yl)-4-methyl-2-(4-methylthiazol-2-yl)-2,3,4,5-tetrahydropyrido[3,2-f][1,4]oxazepin-8-amine (20.00 mg, 10.63 %)

出典と根拠

ORDレコード
ord-d9ed07514588414a96d99512916e6b2b
出典データセット
750 AstraZeneca ELN dataset
元リンク
出典を表示

関連ノート

読み込み中…